A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).Bilal A. Siddiqui, Elizabeth Miller, William Kevin Kelly et al.|Journal of Clinical Oncology|2025Cited by 4
Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)Bilal A. Siddiqui, Elizabeth Miller, Jingsong Zhang et al.|Cancer Research|2025Cited by 3